Bipolar Disorder Screening Tests: MDQ, HCL-32, and Their Limitations
Author: Ukrainian Psychological Hub · Published: October 9, 2026 · Editorial Policy
Bipolar screening tests can help bring a previously overlooked history of mania or hypomania into a clinical conversation. The Mood Disorder Questionnaire (MDQ) and the 32-item Hypomania Checklist (HCL-32) ask about periods of unusually elevated, irritable, or energized mood and associated changes in behavior. They are screening instruments, not diagnostic tests. A positive result signals that a careful assessment may be worthwhile; a negative result cannot conclusively rule out bipolar disorder. The distinction matters because the meaning of a score depends on the person, the setting, the instrument version, and the clinician's evaluation of actual mood episodes. NIMH and a comprehensive diagnostic-accuracy meta-analysis explain why an episode-based clinical history remains essential.
Readers searching for a “bipolar disorder test” often want to know whether changes in energy, sleep, irritability, or depression mean that they have bipolar I or bipolar II disorder. These questions deserve a structured clinical assessment that establishes episode duration, changes from the person's usual functioning, degree of impairment, and possible alternative explanations. Importantly, the NICE bipolar disorder guideline explicitly advises clinicians not to use questionnaires to identify bipolar disorder in adults in primary care. Research in specialist and psychiatric settings has examined the potential use of MDQ and HCL-32 as auxiliary screening tools, but these different contexts must not be treated as interchangeable.
For additional clinical context, see How Is Bipolar Disorder Diagnosed? Clinical Assessment Explained and Bipolar I vs Bipolar II: Differences in Episodes, Diagnosis, and Course.
What is a bipolar disorder screening test?
A bipolar screening test is a questionnaire designed to flag a pattern that deserves diagnostic exploration. Most instruments ask whether the person has experienced a distinct past period of increased energy, activity, confidence, talkativeness, impulsivity, irritability, or reduced need for sleep. The answers are compared with a predefined scoring rule. The result estimates whether the particular pattern captured by the questionnaire is present; it does not establish the clinical syndrome that produced it. In validation research, a diagnostic interview, rather than the screening form, serves as the reference standard. Hirschfeld et al. developed the MDQ for precisely this screening purpose.
Three different activities are sometimes confused. Screening identifies people whose histories may warrant more investigation. Clinical assessment reconstructs whether episodes occurred and considers competing causes. Diagnosis integrates that evidence against current clinical criteria. A fourth activity, monitoring, follows symptoms and functioning after assessment or treatment. A mood-tracking app may be useful for monitoring and still be poorly suited to diagnosing a lifetime bipolar disorder. The distinction is consistent with the VA/DoD 2023 guideline and the NIMH description of diagnostic evaluation.
Why bipolar disorder can be difficult to recognize
Many people seek help during depression, when the relevant history of elevated mood is no longer visible. Hypomanic periods can be remembered as unusually productive or sociable rather than as symptoms. Other people recall increased irritation or reduced sleep without identifying the episode as a distinct change. Family members may remember changes that the person did not notice at the time. This retrospective challenge is central to bipolar assessment. The NIMH notes that bipolar II disorder may remain unrecognized when people seek care for depressive episodes and hypomania goes unnoticed.
A clinical bipolar diagnosis rests on recognizable episodes, not an accumulated list of lifelong traits. Mania involves an abnormally and persistently elevated, expansive, or irritable mood with increased activity or energy and sufficient duration or severity, often accompanied by major functional disruption. Hypomania involves a distinct observable change lasting at least four consecutive days under DSM-based criteria and does not reach the marked impairment, psychosis, or hospitalization-associated severity that makes an episode manic. Bipolar II disorder requires a history of hypomania and major depression, and it can be profoundly disabling through depression and recurrence. NIMH provides an accessible clinical overview. A questionnaire score cannot determine which diagnostic category applies.
The Mood Disorder Questionnaire (MDQ)
The MDQ, first published by Hirschfeld and colleagues in 2000, is a brief self-report instrument built around a lifetime history of manic or hypomanic symptoms. Its familiar format contains 13 yes/no symptom questions, followed by a question about whether several reported symptoms occurred during the same period and another about how much difficulty those symptoms caused. The sequence matters: endorsing multiple behaviors across unrelated years does not necessarily describe a mood episode.
How the MDQ is commonly scored
The original conventional positive-screen rule combines at least seven endorsed symptom items, concurrence of symptoms in the same period, and moderate or serious associated problems. Different research protocols have sometimes omitted the impairment requirement or used alternative thresholds. These variations change screening sensitivity and specificity. The original instrument and scoring logic are described in Hirschfeld et al. (2000) and examined in Zimmerman et al. (2009).
A score of seven is a screening cutoff in a particular scoring algorithm, not a medical threshold that turns a person into a bipolar patient. Seven “yes” answers alone do not satisfy the original complete rule, and satisfying that rule still does not establish a diagnosis. A clinician must explore whether the experiences were episodic, whether they occurred together, how long they lasted, whether others observed them, and whether substances, medications, or another condition better explain them.
What the MDQ does relatively well
The MDQ provides a compact prompt for recalling an elevated or irritable period that might otherwise be omitted from a consultation focused on depression. Under some conditions, it is reasonably specific, meaning that a relatively high proportion of people without bipolar disorder screen negative. However, diagnostic accuracy varies markedly by setting and subtype. In a 2015 meta-analysis of 53 studies, summary sensitivity was 66% and specificity 79% for the MDQ in psychiatric services at recommended cutoffs. Those are pooled research estimates, not promises about an individual respondent.
What the MDQ can miss
The MDQ may miss people with bipolar II disorder, less disruptive hypomania, incomplete recall, or limited insight into past episodes. In a small clinical validation sample, Miller et al. (2004) reported substantially lower MDQ sensitivity for bipolar II or otherwise specified presentations than for bipolar I. Another psychiatric outpatient study found 63.5% sensitivity using the original recommended scoring criteria. A negative screen is therefore insufficient evidence to dismiss a convincing clinical history.
The 32-item Hypomania Checklist (HCL-32)
The HCL-32 was developed to improve recognition of hypomanic experiences, especially among people presenting with depressive symptoms. Its 32 items ask about patterns of activity, confidence, sociability, ideas, irritability, and risk-taking during an unusually “high” period. The questionnaire explores experiences that people may have viewed as beneficial as well as those that generated difficulty. Its original research emphasized an active or elated group of symptoms alongside a risk-taking or irritable group. Angst et al. (2005) documented its development and early clinical validation.
The HCL-32 often uses a count of endorsed symptoms, with 14 frequently studied as a threshold. A cutoff is specific to the version, language, population, and validation study. There is no universal score that independently establishes bipolar disorder. The original study found sensitivity around 80% and specificity around 51% when distinguishing bipolar from major depressive disorder in its samples; subsequent studies reported varying results. Angst et al. and a later systematic review by Meyer and colleagues provide the underlying evidence.
Strengths and tradeoffs of the HCL-32
By placing greater emphasis on the recognition of hypomanic experiences, the HCL-32 may detect cases that a stricter MDQ threshold misses, particularly bipolar II presentations in some psychiatric settings. That increased sensitivity generally comes with more false positives. In a 2015 meta-analysis, summary sensitivity and specificity for the HCL-32 in psychiatric services were 81% and 67%. A 2014 systematic review likewise found that specificity differed depending on whether the comparison group consisted of patients with unipolar depression or a wider range of diagnoses.
The checklist also asks about symptoms without independently proving the clinical duration, observable departure from baseline, or full consequences that establish a hypomanic episode. A person with longstanding energy, ADHD traits, anxiety, or a history of substance use may endorse relevant items for reasons other than bipolar illness. Likewise, an HCL-32 result cannot tell a clinician whether the person has bipolar I rather than bipolar II. The original validation paper identified this subtype limitation directly.
MDQ vs HCL-32: which screening test is more accurate?
There is no context-free winner. Accuracy depends on whether the goal is to minimize overlooked bipolar II presentations, avoid false positives, or assess a particular population. In psychiatric samples, the HCL-32 often achieves higher sensitivity, while the MDQ often has higher specificity. A 2019 systematic review and meta-analysis that compared the two tools in the same patient samples found pooled sensitivity of 82% for HCL-32 and 80% for MDQ, and pooled specificity of 57% for HCL-32 and 70% for MDQ. The review included nine studies in its meta-analysis. These figures describe the included studies using their study-defined cutoffs; they cannot be applied automatically to every clinic or version.
An additional question is whether responses remain stable over time. In a 2026 longitudinal study, 331 adults already diagnosed with bipolar disorder completed the MDQ and HCL-32 at baseline and three months later. HCL-32 scores showed better internal consistency and test–retest reliability than MDQ scores, and both instruments were related to current mood state. Recruitment required meeting an MDQ threshold at baseline, so the study cannot establish comparative sensitivity for detecting previously undiagnosed bipolar illness in an unselected population. These findings address longitudinal measurement reliability, a different outcome from diagnostic accuracy. See Tröger et al. (2026).
The broader Carvalho et al. meta-analysis pooled many more accuracy studies and reported different MDQ estimates. That difference is expected when inclusion criteria, settings, populations, and scoring rules change. The same review found the HCL-32 more accurate than the MDQ for detecting bipolar II in mental health care centers, although several underlying studies were at risk of bias. This is comparative evidence about test performance, not evidence that HCL-32 alone should determine diagnosis or treatment.
Clinical interpretation should also consider the question being asked. A high-sensitivity checklist may be attractive when missing a significant episode history would carry costs. A higher-specificity instrument may reduce unnecessary diagnostic follow-up in a particular referral population. Clinical guidelines, however, can recommend different practice pathways from those suggested by test accuracy alone because usefulness, harms, referral capacity, and quality of evidence also matter.
What sensitivity, specificity, and predictive value actually mean
Sensitivity is the proportion of people who truly have the target disorder and receive a positive screen. A test with 80% sensitivity misses about 20 out of every 100 affected people in a population comparable to the validation sample. Specificity is the proportion of people without the target disorder who receive a negative screen. With 70% specificity, about 30 out of every 100 unaffected people in that sample could screen positive. These numbers are conditional on the study population and reference diagnosis; they are not personal probabilities. The underlying estimates and their variability are documented by Wang et al. (2019).
Positive predictive value answers a different question: among people who screen positive, what proportion actually have the disorder? It depends strongly on how common bipolar disorder is in the population being tested. Even a fairly specific instrument can produce many false positives when used among people with low prior probability of the disorder. Negative predictive value likewise changes with the underlying prevalence. The general-population MDQ validation study reported only 28.1% sensitivity despite 97.2% specificity, illustrating why a favorable number on one measure does not establish broad screening reliability.
A useful way to interpret the literature is to ask five questions before accepting an accuracy claim: Were participants recruited from psychiatric care, general practice, or the general population? Did the researchers use a structured diagnostic interview? What cutoff and version of the tool were used? Which bipolar diagnoses counted as the target condition? Was the comparison group mainly people with major depression, or did it include ADHD, anxiety, trauma-related conditions, and other psychiatric presentations? Without these details, a headline about a “90% accurate bipolar test” has little clinical meaning.
Why a positive bipolar screening result may be misleading
Questionnaire items describe experiences shared by multiple conditions. Periods of restlessness, poor sleep, irritability, increased speech, distractibility, or impulsive decisions may occur with anxiety, ADHD, trauma-related symptoms, substance use, other psychiatric illnesses, medication effects, or major life stress. A screening form can capture these experiences without proving that they occurred as a distinct manic or hypomanic episode.
Evidence for this overlap comes from the Rhode Island MIDAS outpatient study. Among participants without a lifetime bipolar diagnosis, positive MDQ screens were associated with several other psychiatric diagnoses, including posttraumatic stress disorder, substance use disorders, attention-deficit disorder, and impulse-control disorders. The finding establishes that false-positive screens can reflect clinically important symptoms requiring care, while the resulting diagnosis may be different from bipolar disorder.
A positive screen can also arise when endorsed experiences happened at different times, were part of someone's usual temperament, or occurred only during intoxication or a medication-related change. An unusually energetic week during a stressful project is not automatically hypomania. Clinicians need the timeline, the departure from baseline, the constellation of concurrent symptoms, and corroborating information when available. The NICE assessment guidance specifies a detailed history of mood and behavior, relapses, triggers, functioning, comorbidities, and family history.
Why a negative bipolar screening result can also be misleading
A person might not remember past elevated periods, might interpret them positively, or might not recognize the impact on relationships and work. Depression can dominate their current memory of illness. Some brief questionnaires place considerable weight on impairment, yet hypomania can occur without the marked disruption that defines mania. In addition, the MDQ was developed in diagnostic contexts and populations that may not represent everyone completing an online copy today. Miller et al. and Zimmerman et al. document concrete false-negative concerns.
A negative result does not settle the question when there have been distinctive periods of substantially reduced need for sleep, greatly increased energy, unusual confidence, racing thoughts, pronounced impulsivity, or changes noticed by others. The same applies when recurrent depression and a strong family history raise an independent reason for deeper inquiry. Evaluation should follow the clinical history rather than the direction of the score. NIMH describes diagnosis through symptoms across the lifespan, family history, severity, frequency, and duration.
Do guidelines recommend routine bipolar screening?
Guidelines and studies need to be read together. Research demonstrates that some screening instruments can discriminate between selected groups with varying degrees of accuracy. Whether clinicians should routinely administer one is a separate clinical policy question.
The NICE CG185 recommendation 1.2.3 specifically says not to use questionnaires in primary care to identify bipolar disorder in adults. Instead, it advises asking adults presenting with depression about past overactivity or disinhibited behavior and considering specialist referral when such behavior lasted four days or more. NICE also advises against questionnaires to identify bipolar disorder in children and young people in primary care. This guidance should not be replaced by a positive interpretation of a validation study.
The VA/DoD 2023 bipolar guideline organizes care around diagnosis, triage, and appropriate specialist treatment. The CANMAT/ISBD 2023 evidence update addresses evidence-based treatment decisions once bipolar illness and phase are assessed. Neither a pharmacotherapy algorithm nor a checklist score substitutes for establishing the diagnostic history. Screening may be considered within a clinician's broader workflow where appropriate, but educational resources should not present universal questionnaire-based screening as a settled professional standard.
What actually happens during a professional bipolar assessment?
A clinician usually begins with the person's current concerns and a longitudinal timeline. Relevant topics include each period of depression or unusual activation; age at onset; the amount and type of sleep; changes in energy, activity, speech, judgment, spending, sexuality, and risk-taking; and the effects on school, work, finances, safety, and relationships. Duration and clustering of symptoms are central. The assessment also explores whether anyone else noticed a clear change and whether episodes resolved between periods of illness. These elements align with NICE's specialist assessment recommendations.
The interview then considers past medication exposure, especially antidepressants, stimulants, corticosteroids, and other agents that might affect mood or energy, together with alcohol and other substances. Medical conditions and sleep-related problems may require evaluation. Personal and family psychiatric history can help contextualize the presentation without determining diagnosis by itself. A physical examination or laboratory testing may be used when necessary to exclude medical contributors, but there is no routine blood test or brain scan that independently confirms bipolar I or bipolar II disorder. NIMH describes the complementary role of medical evaluation and mental health assessment.
Structured or semistructured diagnostic interviews can organize the process, particularly when histories are complicated. Clinicians may ask a trusted relative or partner about behavior during possible episodes, with appropriate consent and sensitivity to the person's preferences and safety. The final formulation must integrate the interview, functional impact, differential diagnosis, and longitudinal course. A bipolar screening form, even when completed before the appointment, contributes one limited piece of information to that process.
Can the MDQ or HCL-32 diagnose bipolar I, bipolar II, or cyclothymia?
No. Bipolar I disorder requires a qualifying manic episode; bipolar II requires qualifying hypomanic and major depressive episodes without a history of mania. Cyclothymic disorder involves a prolonged course of fluctuating hypomanic and depressive symptoms that do not meet the full episode requirements and has its own duration and exclusion criteria. These categories depend on episode structure, longitudinal history, and clinician judgment, rather than the total number of boxes checked. See the NIMH diagnostic overview.
The difference between mania and hypomania is especially consequential. Psychotic symptoms during an elevated episode and severe impairment can change the diagnostic interpretation; calling every activated period “hypomania” can conceal the need for urgent care. Conversely, bipolar II is not simply a mild version of bipolar I, because depressive episodes and long-term impairment can be substantial. Both the original HCL-32 paper and the MDQ subgroup study demonstrate limitations in subtype discrimination and detection.
What other questionnaires may be used?
The Bipolar Spectrum Diagnostic Scale (BSDS) is another researched screening instrument. It uses a narrative presentation of possible bipolar-spectrum experiences and asks respondents to indicate what fits their history. A 2005 clinical validation study evaluated its sensitivity and specificity, while the 2015 meta-analysis compared it with the MDQ and HCL-32. As with the other tools, any apparent performance advantage is bound to the study population and cutoff.
The Rapid Mood Screener (RMS) is another brief instrument studied primarily for identifying bipolar I presentations among people experiencing depression. Its questions, population, and target condition differ from those of the MDQ and HCL-32, and estimates derived from its validation studies should not be treated as directly comparable to every MDQ or HCL-32 study. A 2025 review of bipolar screening tools examines RMS alongside MDQ, HCL-32, and BSDS while emphasizing the continuing need for diagnostic interviews.
Some diagnostic interview modules and clinical rating scales are intended for different purposes. For example, a structured diagnostic interview seeks to determine whether criteria are met, while a mania rating scale measures the severity of symptoms in someone currently being assessed. Treating all these instruments as interchangeable “bipolar tests” creates confusion about their actual function. A clinician can explain why a particular tool is being used and what decision it is intended to inform.
Can an online bipolar disorder quiz tell you whether you have bipolar disorder?
An online quiz can raise questions worth discussing, but its result should never be treated as a diagnosis, a subtype classification, or a medication recommendation. Websites may change item wording, omit original sections, apply unofficial thresholds, provide no validation data for their adaptation, or generate a confident-sounding interpretation of an incomplete history. Published evidence for a standardized MDQ or HCL-32 does not automatically validate a shortened or redesigned web version. The original MDQ validation and the HCL-32 systematic review studied specified measures under defined research conditions.
If someone has already completed a quiz, the most useful information to bring to a clinician is the particular experiences behind the answers: when they occurred, whether symptoms overlapped in time, what the person's ordinary baseline is, and how the episode affected functioning. Screenshots or a score can be brought as a conversation aid, but they should not displace this account.
How screening results relate to other diagnoses
Depression and bipolar depression
Depression appears in both unipolar major depressive disorder and bipolar disorders. A depression questionnaire measures depressive symptoms; it does not establish whether past mania or hypomania occurred. When evaluating recurrent depression, clinicians examine previous periods of abnormal energy and activity because the longitudinal diagnosis affects treatment planning. The assessment question belongs with bipolar diagnostic evaluation, while a full discussion of unipolar depression belongs to the depression clinical territory. NIMH describes why depressive presentations can obscure bipolar II.
ADHD and persistent traits
ADHD symptoms often begin early and persist across settings, whereas bipolar mood episodes represent a change from the person's usual state over a defined period. Distractibility, restlessness, impulsivity, and rapid speech can appear in both conditions, so an MDQ-positive result must be investigated rather than automatically interpreted as bipolar illness. Some people have both conditions, and one diagnosis does not preclude the other. In outpatient research, Zimmerman and colleagues observed associations between nonbipolar positive MDQ screens and attention-related diagnoses.
Borderline personality disorder, trauma, and anxiety
Mood reactivity, emotional intensity, disturbed sleep, agitation, and impulsivity can be present in several psychiatric conditions. Differentiation requires an account of temporal pattern, triggering contexts, enduring features, clinically defined episodes, and comorbidity. It is possible for two conditions to coexist, so the assessment is not always an either-or choice. A study of MDQ screening among psychiatric inpatients illustrates the challenge of distinguishing bipolar disorder and borderline personality disorder from screening responses alone. Zimmerman et al. also identified trauma- and anxiety-related diagnoses among nonbipolar people with positive screens.
Psychosis, substances, and medical causes
Psychosis may occur during a manic or depressive episode, but its timing relative to mood episodes is relevant to differential diagnosis. Intoxication, withdrawal, medications, and medical conditions may cause states that resemble mania or hypomania. Clinicians should clarify these relationships before assigning a primary bipolar diagnosis. The VA/DoD guideline and NIMH support a comprehensive approach to diagnosis and triage.
Related diagnostic questions can arise when obsessive-compulsive symptoms overlap with mood changes. The distinctions between compulsions, intrusive thoughts, and episodic mood elevation are explored in OCD vs Bipolar Disorder.
Special considerations for adolescents, pregnancy, and later life
The MDQ and HCL-32 evidence reviewed here primarily concerns adult samples. Findings should not automatically be transferred to children, adolescents, older adults, pregnant patients, or postpartum patients. Developmental changes, medical comorbidity, medication exposure, sleep disruption, and the clinical meaning of increased activity can differ across groups. NICE CG185 specifically calls for specialist assessment pathways for young people and advises against primary-care questionnaires for this purpose.
In pregnancy and the postpartum period, new mood elevation, markedly reduced need for sleep, confusion, or psychotic symptoms requires a promptly individualized professional assessment. Screening instruments validated in general psychiatric samples do not establish the safety or clinical significance of these presentations. A clinician should consider reproductive and postpartum context together with mood history and current functioning. A score should never prompt a patient to start, stop, or alter psychiatric medication independently. The NICE guideline provides specialist care considerations for pregnancy planning and treatment.
What should you do after a positive or negative screen?
A positive result is a reason to document the relevant experiences and discuss them with an appropriately qualified professional. Write down approximate dates, how many days the changes lasted, hours slept, whether you felt tired, any unusual actions, feedback from other people, and effects on work or relationships. Include medication and substance exposures. Ask the clinician which explanations fit the full pattern and what further assessment would change the conclusion.
After a negative result, seek an assessment anyway if the personal history contains credible episodes that concern you or people close to you. The value of the consultation does not depend on arriving at a bipolar diagnosis; evaluating persistent depression, anxiety, sleep problems, and functional difficulties is worthwhile on their own terms. The NIMH and NICE place the emphasis on careful evaluation and appropriate referral.
If you are already receiving treatment for depression or another condition, discuss any periods of unusual activation, agitation, greatly decreased need for sleep, or major behavior change with your prescriber. Some treatment decisions depend on distinguishing unipolar from bipolar depression, but a screening score is not a basis for changing medication. Treatment of acute mania, bipolar depression, and long-term relapse prevention each requires its own evidence-based plan. The CANMAT/ISBD 2023 update and VA/DoD 2023 guideline describe the importance of phase-specific clinical management.
When a screening questionnaire should not delay urgent care
Immediate safety concerns override routine screening. Seek urgent medical or emergency mental health evaluation when someone is experiencing severe behavioral disorganization, dangerous judgment, psychotic symptoms, escalating mania with very little sleep, or thoughts of suicide with imminent risk. A family member or friend may need to assist in contacting emergency services when a person cannot safely seek help independently. NICE advises urgent specialist referral for suspected mania, severe depression, or danger to self or others; the VA/DoD guideline addresses diagnosis and triage.
Someone in immediate danger should contact local emergency services. In the United States, 988 connects to the Suicide & Crisis Lifeline. This guidance applies regardless of an MDQ or HCL-32 score, and a screening form should never delay a safety assessment.
Common misunderstandings about bipolar tests
A high score does not prove that someone has bipolar disorder. A low score does not exclude bipolar II. The HCL-32 is not a more definitive “test” merely because it contains more questions. A questionnaire is not equivalent to a structured clinical interview. A positive screen among people living with ADHD, anxiety, trauma-related symptoms, or substance use is not automatically a false experience; it may represent genuine distress whose cause still needs clarification. And a clinical diagnosis cannot be established by comparing one person's online score with another person's score. These conclusions follow from the validation designs and setting-dependent accuracy documented by Carvalho et al., Wang et al., and Zimmerman et al..
Frequently asked questions
Is there a reliable test for bipolar disorder?
There are researched screening questionnaires and structured diagnostic interviews, but no single online questionnaire, blood test, or scan independently establishes bipolar disorder. Reliability and accuracy depend on the method and setting. Diagnosis requires a clinical account of episode history, severity, duration, impairment, differential diagnosis, and relevant medical history. See NIMH.
What does a positive MDQ mean?
It means your responses met a specified screening rule, if the complete validated form and scoring algorithm were used. It indicates the possibility that your history warrants a clinician's assessment. It does not establish bipolar I or bipolar II and does not justify medication changes. The original MDQ validation was explicitly a screening study.
What is a normal HCL-32 score?
There is no universal “normal” cutoff that can tell an individual whether they have bipolar disorder. A threshold around 14 has appeared in validation research, but the appropriate interpretation depends on the population, language version, and setting. Higher endorsement counts do not automatically correspond to greater clinical severity. See Angst et al. and Meyer et al..
Which is better for detecting bipolar II: MDQ or HCL-32?
Some evidence from mental health settings favors the HCL-32 for sensitivity to bipolar II presentations, while the MDQ may be more specific. Results differ by study and scoring algorithm. Neither one can diagnose bipolar II or reliably exclude it after a negative screen. See Carvalho et al. (2015) and Wang et al. (2019).
Can ADHD cause a positive MDQ result?
ADHD-associated behaviors can overlap with questionnaire symptoms, and positive MDQ screens have occurred among people with attention-related diagnoses who did not have bipolar disorder. A clinician differentiates persistent patterns from distinct mood episodes and also considers possible comorbidity. See Zimmerman et al..
Should I take a bipolar test while feeling depressed?
Depression may be an appropriate reason to discuss prior unusually energized or disinhibited periods with a clinician. Whether a questionnaire helps depends on the clinical setting and local guidance. NICE advises clinicians in primary care to inquire about history rather than use bipolar-identification questionnaires as a routine primary-care method. See NICE CG185.
Can my doctor diagnose me from an MDQ or HCL-32 score?
A clinician may consider the answers but needs a fuller history and diagnostic assessment. A positive screening result is only one piece of clinical information, and any diagnosis should account for the actual timing and impact of episodes, alternative explanations, and relevant history. See VA/DoD 2023.
What if my online quiz says “high probability” of bipolar disorder?
Treat that phrase as an interpretation made by the website, not as a clinical probability personalized to you. Many online quizzes provide no evidence that their version, scoring, or probability estimate was validated. Use your concerns and examples of episodes to request a professional evaluation, particularly if changes are recurrent or impairing. The limitations are documented in diagnostic-accuracy research.
The central clinical conclusion
MDQ and HCL-32 can organize questions about past elevated or irritable periods, and research has measured how they distinguish groups of patients under specified conditions. Their scores remain dependent on setting, cutoff, subtype, recall, and overlapping symptoms. Professional diagnosis reconstructs the individual's episode history and considers the full clinical context. Choosing evaluation and treatment on the basis of that history protects against both missed bipolar illness and inappropriate labeling. This conclusion is consistent with the NIMH, NICE, and the Carvalho et al. meta-analysis.
Related Articles
References
Angst, J., Adolfsson, R., Benazzi, F., et al. (2005). The HCL-32: Towards a self-assessment tool for hypomanic symptoms in outpatients. Journal of Affective Disorders, 88(2), 217–233. https://doi.org/10.1016/j.jad.2005.05.011.
Carvalho, A. F., Takwoingi, Y., Sales, P. M. G., et al. (2015). Screening for bipolar spectrum disorders: A comprehensive meta-analysis of accuracy studies. Journal of Affective Disorders, 172, 337–346. https://doi.org/10.1016/j.jad.2014.10.024.
Dines, M., Hernandorena, C., Grasso, V., & Vazquez, G. (2025). Critical overview of screening tools for detecting bipolar disorders. Actas Españolas de Psiquiatría, 53(5), 1122–1130. https://doi.org/10.62641/aep.v53i5.1924.
Ghaemi, S. N., Miller, C. J., Berv, D. A., Klugman, J., Rosenquist, K. J., & Pies, R. W. (2005). Sensitivity and specificity of a new bipolar spectrum diagnostic scale. Journal of Affective Disorders, 84(2–3), 273–277. https://doi.org/10.1016/S0165-0327(03)00196-4.
Hirschfeld, R. M. A., Holzer, C., Calabrese, J. R., et al. (2003). Validity of the Mood Disorder Questionnaire: A general population study. American Journal of Psychiatry, 160(1), 178–180. https://doi.org/10.1176/appi.ajp.160.1.178.
Hirschfeld, R. M. A., Williams, J. B. W., Spitzer, R. L., et al. (2000). Development and validation of a screening instrument for bipolar spectrum disorder: The Mood Disorder Questionnaire. American Journal of Psychiatry, 157(11), 1873–1875. https://doi.org/10.1176/appi.ajp.157.11.1873.
Keramatian, K., Chithra, N. K., & Yatham, L. N. (2023). The CANMAT and ISBD Guidelines for the Treatment of Bipolar Disorder: Summary and a 2023 update of evidence. Focus, 21(4), 344–353. https://doi.org/10.1176/appi.focus.20230009.
Meyer, T. D., et al. (2014). The Hypomania Checklist (HCL)—systematic review of its properties to screen for bipolar disorders. Comprehensive Psychiatry, 55(5), 1310–1321. https://doi.org/10.1016/j.comppsych.2014.03.002.
Miller, C. J., Klugman, J., Berv, D. A., Rosenquist, K. J., & Ghaemi, S. N. (2004). Sensitivity and specificity of the Mood Disorder Questionnaire for detecting bipolar disorder. Journal of Affective Disorders, 81(2), 167–171. https://doi.org/10.1016/S0165-0327(03)00156-300156-3).
National Institute for Health and Care Excellence. (2014; current online guideline). Bipolar disorder: Assessment and management (CG185). https://www.nice.org.uk/guidance/cg185/chapter/recommendations.
National Institute of Mental Health. (n.d.). Bipolar disorder. https://www.nimh.nih.gov/health/publications/bipolar-disorder.
Palmer, B. A., Pahwa, M., Geske, J. R., et al. (2021). Self-report screening instruments differentiate bipolar disorder and borderline personality disorder. Brain and Behavior, 11(7), e02201. https://doi.org/10.1002/brb3.2201.
Tröger, A., Zeng, Y., Richardson, T., Palmer-Cooper, E., Young, A. H., & Strawbridge, R. (2026). Cross-sectional and longitudinal comparison of commonly used screening tools for bipolar disorders. Bipolar Disorders, 28(5), e70133. https://doi.org/10.1111/bdi.70133.
U.S. Department of Veterans Affairs & U.S. Department of Defense. (2023). VA/DoD clinical practice guideline for management of bipolar disorder. https://healthquality.va.gov/HEALTHQUALITY/guidelines/mh/bd/index.asp.
Wang, Y.-Y., Xu, D.-D., Liu, R., et al. (2019). Comparison of the screening ability between the 32-item Hypomania Checklist (HCL-32) and the Mood Disorder Questionnaire (MDQ) for bipolar disorder: A meta-analysis and systematic review. Psychiatry Research, 273, 461–466. https://doi.org/10.1016/j.psychres.2019.01.061.
Zimmerman, M., Galione, J. N., Ruggero, C. J., et al. (2009). Performance of the Mood Disorders Questionnaire in a psychiatric outpatient setting. Bipolar Disorders, 11(7), 759–765. https://doi.org/10.1111/j.1399-5618.2009.00755.x.
Zimmerman, M., Galione, J. N., Ruggero, C. J., et al. (2011). Psychiatric diagnoses in patients who screen positive on the Mood Disorder Questionnaire: Implications for using the scale as a case-finding instrument for bipolar disorder. Psychiatry Research. https://pubmed.ncbi.nlm.nih.gov/20656360/.